38.6c New Delhi, India, Thursday, October 23, 2025
Top Stories Supreme Court
Political NEWS Legislative Corner Celebstreet International Videos
Subscribe Contact Us
close
Business

Dr Reddy's Inks $61 Million Deal To Acquire Cidmus Brand In India From Novartis

By AKSHAT BHAT      04 April, 2022 09:44 PM      0 Comments
Dr Reddy Acquire Cidmus Brand In India From Novartis

Dr. Reddy's Laboratories announced on Friday that it has struck a deal with Novartis AG to purchase the Cidmus cardiovascular medication brand in India for $61 million (about Rs 463 crore). Dr Reddy's will be assigned and transferred the Cidmus trademark in India from Novartis AG for a fee of $61 million, according to a regulatory filing by the Hyderabad-based pharmaceutical company.

The Cidmus brand will be assigned to a pharmaceutical composition that contains a combination of Valsartan and Sacubitril (now patented by Novartis) and is intended for heart failure patients with a reduced ejection fraction, according to the company. The tablets come in three different strengths. Cidmus recorded sales of Rs 136.4 crore in India for the most recent twelve months ending in February 2022, according to IQVIA MAT data.

Dr Reddy's plans to use its large customer base to engage with healthcare professionals, as well as expand the product's reach beyond metros into tier-I and tier-II markets in India, through its strong marketing and distribution network, to provide more access to patients in need, according to the company.

Cidmus' acquisition is yet another endeavour by a large pharmaceutical company to provide access to well-known brands for healthcare professionals and patients. Given the high frequency of cardiovascular disorders in India, this acquisition will enable Dr Reddy's to provide patients with a trusted portfolio of medicines, according to the company. The medication will complement the company's existing cardiovascular portfolio, which includes leading brands like Stamlo, Stamlo Beta, Reclide-XR, and Reclimet-XR, and will help it achieve its goal of breaking into the top 10 cardiac players in the Indian pharmaceutical market, according to the company. It will also boost Dr Reddy's foothold in the chronic area in India, as the company's India business continues to be a strong growth driver and priority market, according to the company.

"Cidmus will be a strong addition to the companys existing portfolio in the cardiovascular segment alongside its leading brands such as Stamlo, Stamlo Beta, Reclide-XR and Reclimet-XR, and will take it closer to its ambition of breaking into the top 10 cardiac players in the Indian pharmaceutical market," the company said.
It will also strengthen the presence of Dr. Reddys in the chronic space in India as its India business continues to be a solid growth driver and focus market.



Share this article:



Leave a feedback about this
TRENDING NEWS


TOP STORIES

father-of-deceased-pilot-in-ahmedabad-crash-moves-sc-for-court-monitored-probe
Trending Judiciary
Father of deceased pilot in Ahmedabad crash moves SC for court monitored probe

91-year-old father of pilot killed in Ahmedabad Air India crash moves SC seeking court-monitored probe into alleged biased and flawed investigation.

17 October, 2025 10:54 AM
child-cant-consent-to-sex-life-imprisonment-upheld-for-sexual-assault-on-minor-girl-madras-hc
Trending Judiciary
Child Can’t Consent to Sex — Life Imprisonment Upheld for Sexual Assault on Minor Girl: Madras HC [Read Judgment]

Madras HC upholds life imprisonment for assault on minor SC girl, reiterating that a child cannot consent to sex; school records key for age proof.

17 October, 2025 11:45 AM
sc-criticizes-casual-declaration-of-witnesses-as-hostile-upholds-conviction-under-sc-st-act
Trending Judiciary
SC Criticizes Casual Declaration of Witnesses as Hostile, Upholds Conviction under SC/ST Act [Read Judgment]

Supreme Court slams casual practice of declaring witnesses hostile; upholds life imprisonment in SC/ST Act case involving rape of minor girl.

17 October, 2025 11:55 AM
delhi-hc-quashes-22-year-old-complaint-against-advocate-reiterates-that-a-lawyers-office-is-not-a-commercial-activity
Trending Judiciary
Delhi HC Quashes 22-Year Old Complaint Against Advocate, Reiterates That A Lawyer’s Office Is Not A Commercial Activity [Read Judgment]

Delhi HC quashes 22-year-old complaint against advocate, rules that a lawyer’s office is not a commercial activity under MDP 2001 and Building Bye-Laws.

17 October, 2025 01:42 PM

ADVERTISEMENT


Join Group

Signup for Our Newsletter

Get Exclusive access to members only content by email